Sign in
Taking people in United StatesPhase 2

LGG Supplementation in Patients With AUD and ALD

Key facts

Who runs it
University of Louisville
Where
Louisville, United StatesSee the site
Trial code
Status
Recruiting
Phase
Phase 2
People taking part
60 people, planned
Started
1 Jun 2022
Expected to end
28 Feb 2027
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • : Placebo for Probiotic
  • Lactobacillus Rhamnosus GG
Record updated
31 October 2025

Who can take part

Age
21 years to 65 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (30)Hide the full registry criteria

Who can take part

  • Breath alcohol concentration (BAC) equal to 0.00 when the participant signs the informed consent document
  • Age between 21 and 65 years old (inclusive)
  • Willingness to receive trial treatment
  • Ability to provide informed consent
  • Understanding that this is not an alcohol treatment study
  • Heavy drinking. Men must consume ≥ 20 and women ≥ 14 standardized alcoholic beverages a week for the past 3 months
  • Diagnosis of Alcohol Use Disorder using DSM V criteria
  • 50 <AST<400 U/L; AST > ALT; and ALT < 200 U/L; total bilirubin > 1.2 mg/dL
  • Model for End-Stage Liver Disease: 8 ≤ (MELD) ≤19
  • Good health as confirmed by medical history, physical examination, ECG, laboratory tests and vital signs except for liver injury and AUD related history
  • Provide contact information for someone who may be able to contact the subject in case of a missed appointment
  • . Females of child-bearing potential must not be pregnant and must be using birth control

Who cannot take part

  • Positive urine drug screen at baseline for any illegal substance other than marijuana,
  • Participation in any research study for alcoholism treatment within 3 months prior to signing the informed consent,
  • Pharmacological treatment with naltrexone, acamprosate, topiramate, or disulfiram within 1 month prior to randomization,
  • Current use of psychotropic medications that cannot be discontinued,
  • Acute gastrointestinal bleeding requiring > 2 units blood transfusion within the previous 2 weeks
  • History of hospitalization for alcohol intoxication delirium, alcohol withdrawal delirium or seizure,
  • Lifetime diagnosis based on DSM-V criteria of schizophrenia, bipolar disorder, or other psychosis, eating disorders; current or past year diagnosis of major depression
  • Serious medical diseases, such as cancer, liver cirrhosis, pancreatitis, severe alcohol associated hepatitis, heart chronic failure, chronic kidney failure, chronic intestinal diseases (e.g., Crohn's disease), chronic neurological disorders (e.g., tardive dyskinesia, epilepsy, Parkinson's disease)
  • History of clinically significant hypotension (e.g., history of lipotimia and/or syncopal episodes)
  • History of adverse reactions to needle puncture,
  • Signs of systemic infection: Fever > 38o C, positive blood or ascites cultures, on appropriate antibiotic therapy for > 3 days within 3 days of inclusion
  • Undue risk from immunosuppression: Positive HBsAg; positive skin PPD skin test or history of treatment for tuberculosis; known HIV infection
  • Current (last 12 months) DSM V diagnosis of dependence on any psychoactive substance other than alcohol or nicotine,
  • In the investigators' opinion, moderate to severe risk of suicide (e.g., active plan, or recent attempt in last 6 months),
  • Clinically significant medical abnormalities (apart from moderate ALD, MELD≤19),
  • Clinical Institute Withdrawal Assessment for Alcohol revised (CIWA-Ar) >10, at screening for more than 3 days,
  • Obesity (BMI ≥ 33.0 kg/m2),
  • Pregnancy; incarceration; inability to provide consent

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Alcohol use disorder or alcohol-associated liver disease

This trial is currently available in United States.

  • University of Louisville HospitalLouisville, United StatesContact: Vatsalya Vatsalya, MD, PgD, MSc, MS, FRSMTaking people

About the trial

What the trial wants to find out

To test the efficacy of 6-month LGG compared to placebo in treating Alcoholic Use Disorder (AUD) and liver injury in Alcoholic Hepatitis (AH). And to evaluate the effects of LGG treatment compared to placebo on therapeutic-mechanistic markers of the gut-brain axis and pro-inflammatory activity in patients with AUD and moderate AH

The 2 groups in the trial

  • Placebo Comparator: Placebo for ProbioticPlacebo, for comparison

    Placebo capsule that matches the probiotic capsule in appearance will be given once daily for 180 days.

    Treatment: : Placebo for Probiotic

  • Active Comparator: Lactobacillus Rhamnosus GGExisting treatment, for comparison

    Dietary supplement capsule (Lactobacillus Rhamnosus GG) will be given once daily for 180 days.

    Treatment: Lactobacillus Rhamnosus GG

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Lactobacillus Rhamnosus GG: A Novel Probiotic Therapy for Treating Alcohol Use Disorder
Criteria questions
Built from NCT05178069, who can take part
Record updated
31 October 2025